Patents by Inventor Tarik Ali KHAN

Tarik Ali KHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR THE DETERMINATION OF HYDROLYTIC ACTIVITY
    Publication number: 20230358748
    Abstract: Herein is reported a method for determining the presence of hydrolase activity in a sample by incubating the sample in a buffered solution, which comprises an artificial hydrolase substrate that comprises an ester bond covalently linking an alcohol residue, which is conjugated to a label for removal, and a carboxylic acid residue, which is conjugated to a capture and detection label, as well as bovine serum albumin, and thereafter determining or quantifying, respectively, the released carboxylic acid in the free alcohol depleted incubation mixture.
    Type: Application
    Filed: December 16, 2022
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Franziska EDELMANN, Roberto FALKENSTEIN, Tobias GRAF, Sanjay GUPTA, Lars HILLRINGHAUS, Tarik Ali KHAN, Michael LEISS, Thomas MEIER, Michael WIEDMANN
  • PREVENTION OF VISIBLE PARTICLE FORMATION IN PARENTERAL PROTEIN SOLUTIONS
    Publication number: 20230167172
    Abstract: The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, as well as compositions and pharmaceutical products obtained with said method.
    Type: Application
    Filed: November 10, 2022
    Publication date: June 1, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Keijiro HATADE, Stefan Josef FISCHER, Christina Roswitha HAEUSER, Stephen Alfred HYLAND, Tarik Ali KHAN, Ralph LOVIS, Satya Krishna Kishore RAVURI, Hitoshi SASAKI
  • Subcutaneous HER2 antibody formulations
    Patent number: 11654105
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 23, 2023
    Assignees: Genentech, Inc., Hoffmann-La Roche
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20230092354
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: August 22, 2022
    Publication date: March 23, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
    Publication number: 20210085597
    Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 25, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
  • Engineered polypeptides for antigen delivery
    Patent number: 10450352
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: October 22, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer Maynard, Xianzhe Wang, Tarik Ali Khan
  • ENGINEERED POLYPEPTIDES FOR ANTIGEN DELIVERY
    Publication number: 20190106463
    Abstract: Recombinant high affinity Invasin polypeptide are provided herein. Further provided are methods of delivering therapeutics such as vaccines by conjugation to the engineered recombinant Invasin polypeptides.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 11, 2019
    Inventors: Jennifer MAYNARD, Xianzhe WANG, Tarik Ali KHAN